CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 1,220 enrolled
Drug / intervention
Aspirin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02616497
NCT02616497Phase 4Completed
CompareCT.gov

Comparison of Triflusal With Aspirin in the Secondary Prevention of Atherothrombotic Events

University of Ioannina·interventional·Posted Nov 30, 2015·Updated Apr 17, 2018

In Brief

A Phase 4 clinical trial evaluating Aspirin and Triflusal for Atherothrombosis. Completed, enrolled 1,220 participants across 1 site.

Detailed Summary

Investigation of the efficacy and safety of triflusal in comparison with aspirin in patients with stable coronary artery disease (CAD) and in those with a history of an acute non-cardioembolic ischemic stroke.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtherothrombosis
CountriesGreece
Collaborators--

Timeline

Phase 4CompletedFinished
20162017201820192020202120222023202420252026
First PostedNov 30, 2015
Enrollment StartSep 1, 2015
Primary CompletionFeb 28, 2017
Study CompletionMar 28, 2018
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 10.6 years ago

Interventions

Aspirindrug

COX-1 inhibitor

Triflusaldrug

COX-1 inhibitor